<DOC>
	<DOCNO>NCT00270530</DOCNO>
	<brief_summary>Prevention malaria pregnancy critical give high incidence malaria Zambia serious impact maternal infant survival . Intermittent presumptive treatment sulfadoxine-pyrimethamine show highly efficacious reduce risk malaria pregnancy . However , base study do western Kenya , HIV-infected pregnant woman may need frequent dose SP , i.e. , monthly basis rather standard 2-dose regimen give second third trimester , HIV appear reduce effectiveness SP drug combination . The goal study evaluate efficacy standard dose regimen comparison intensive monthly SP dose schedule HIV-positive woman .</brief_summary>
	<brief_title>Intermittent Preventive Treatment Malaria HIV-Seropositive Pregnant Women Zambia</brief_title>
	<detailed_description>Primary Objectives To compare efficacy IPT monthly SP versus two-dose regimen give second third trimester HIV-infected woman : - Prevalence placental malaria infection - Prevalence maternal peripheral parasitemia Secondary objective To compare IPT monthly SP versus two-dose regimen give second third trimester HIV-infected woman : - Birth weight , include proportion LBW infants - Incidence prematurity - Neonatal fetal death third trimester stillbirth - Incidence neonatal jaundice - Third trimester anemia - Third trimester severe anemia - Proportion mother develop symptomatic malaria course pregnancy</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Stillbirth</mesh_term>
	<mesh_term>Perinatal Death</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>HIVpositive pregnant woman 1628 week gestation identify VCT HIVnegative pregnant woman 1628 week gestation identify VCT Residence within catchment area health facility Willing deliver health facility Willing agree adhere requirement study participation ( include monthly ANC visit willing allow study procedure ) Willing provide write informed consent Aged 18 year Severe anemia ( Hb &lt; 6 g/dL ) History allergic reaction sulfa drug History know pregnancy complication ( e.g . breech presentation , severe preeclampsia , prior caesarian section ) History presence major illness likely influence pregnancy outcome include diabetes mellitus , severe renal heart disease , active tuberculosis , prior randomization Any significant presenting illness require hospitalization Intent move study catchment area delivery deliver relative â€™ home catchment area Prior enrollment study concurrent enrollment another study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Placental disease</keyword>
	<keyword>Birth complication</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Zambia</keyword>
	<keyword>HIV-seropositive</keyword>
	<keyword>HIV</keyword>
</DOC>